Merck stated that there were no approved U.S. monovalent single-antigen vaccines for measles, mumps, or rubella as of 2025-10-06.
October 06, 2025
high
regulatory
Manufacturer statement about available vaccine approvals in the United States.
Merck stated that evidence suggests use of combination vaccines for measles, mumps, and rubella improves childhood vaccination outcomes by increasing both completion (receipt of all recommended doses) and compliance (age-appropriate administration) rates.
October 06, 2025
high
clinical_evidence
Claim about the impact of combination vaccines on vaccination completion and timeliness.